InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,841.47
(
-0.02%
)
US TECH 100
19,694.00
(
0.29%
)
Dow Jones
43,239.05
(
0.37%
)
Brent Oil
74.42
(
0.35%
)
Bitcoin
67,548.96
(
0.19%
)
Post# of 30387
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Gold Seeker

Send PM Follow Ignore
Followers 29
Posts 9421
Boards Moderated 0
Alias Born 04/30/2006

Gold Seeker

Re: HALF FULL GLASS post# 16741

Thursday, 10/09/2008 11:33:05 AM

Thursday, October 09, 2008 11:33:05 AM

Post# of 30387
Half, no that is not true. In a study, you have to have both normals and actual cancers. Specificity is totally based on the normal group and sensitivity is totally based on the cancer group. The only thing common between the two groups is the same cutoff level has to be used for both of them.

We have just never seen any prior data where all of the cancers have RECAF levels up to 4900 and why for the first time has he not included any staging for the cancer group?

I think his objective was to show really good numbers and indeed he did.


Anyone now have any doubts why the FDA requires controlled clincial trials?




Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up